HemoShear Presents Drug Saftey Findings at Toxicology Meeting
Thursday, March 27, 2014
HemoShear, LLC, developer of the most advanced human biology systems for drug research and development, is presenting results from its predictive science at The Annual Society of Toxicology (SOT) Meeting being held in Phoenix, Arizona, March 23-27, 2014. SOT is the world's largest toxicology meeting and is attended by executives and scientists who are responsible for safety assessment of a wide range of drugs, chemicals and materials.
HemoShear will present results of two pharmaceutical company-funded studies that successfully demonstrate the ability of HemoShear's predictive science to explain the differing effects of drugs in animals and humans. HemoShear's work is an important step towards translating the response of animals and humans to new drug candidates, which will enable more accurate predictions of safety and efficacy in humans.
Drug safety researchers have few alternatives to animal models for predicting drug effects prior to testing in humans. To bridge the gap from animals to humans, HemoShear has developed rat, canine, non-human primate and human biological systems to explain species effects, to elucidate differences in biology between species and to determine which species, if any, are most predictive of human response to a specific drug candidate. HemoShear's predictive science accelerates the process of drug development while reducing the number and high cost of drug failures.
Altered Hemodynamics Play a Critical Role in Fenoldopam-Induced Mesenteric Vasculitis in the Rat
Authors: M Simmers, B Cole, A Mackey, D Manka, BR Blackman, BR Wamhoff
HemoShear, LLC, Charlottesville, VA
This study explains the effects of fenoldopam, an anti-hypertensive agent that causes vascular injury in the rat but presents no known vascular injury response in humans.
Preclinical profiling and comparison to a human response database of an in vitro cynomolgus macaque vascular system as a non-human primate surrogate
Authors: M Simmers (1), R Feaver (1), B Cole (1), A Pryor (1), JR Turk (2), D Manka (1), BR Wamhoff (1), CW Qualls, Jr (2), BR Blackman (1)
HemoShear, LLC (1), Amgen, Inc. (2)
This study compares monkey and human vascular response to four marketed statins.